Journal of Substance Abuse Treatment
Volume 38, Issue 2 , Pages 119-127 , March 2010

Structural-level factors affecting implementation of the methadone maintenance therapy program in China

  • Chunqing Lin, Ph.D.

      Affiliations

    • Department of Epidemiology, School of Public Health, University of California at Los Angeles, Los Angeles, CA 90024, USA
    • Corresponding Author InformationCorresponding author. Epidemiology, UCLA School of Public Health, 10920 Wilshire Blvd., Suite 350, Los Angeles, CA 90024, USA. Tel.: +1 310 910 9707; fax: +1 310 794 2495.
    • ,
  • Zunyou Wu, Ph.D.

      Affiliations

    • National Center for AIDS/STD Control and Prevention, Chinese Centers for Disease Control and Prevention, Xuanwu District, Beijing 100050, China
    • ,
  • Keming Rou, B.S.

      Affiliations

    • National Center for AIDS/STD Control and Prevention, Chinese Centers for Disease Control and Prevention, Xuanwu District, Beijing 100050, China
    • ,
  • Wenyuan Yin, M.D.

      Affiliations

    • National Center for AIDS/STD Control and Prevention, Chinese Centers for Disease Control and Prevention, Xuanwu District, Beijing 100050, China
    • ,
  • Changhe Wang, M.S.

      Affiliations

    • National Center for AIDS/STD Control and Prevention, Chinese Centers for Disease Control and Prevention, Xuanwu District, Beijing 100050, China
    • ,
  • Steven Shoptaw, Ph.D.

      Affiliations

    • Department of Family Medicine and Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA 90024, USA
    • ,
  • Roger Detels, M.D., M.S.

      Affiliations

    • Department of Epidemiology, School of Public Health, University of California at Los Angeles, Los Angeles, CA 90024, USA

Received 10 April 2009 ,Revised 1 September 2009 ,Accepted 20 September 2009.

References 

  1. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Review. 2004;18:CD004147
  2. Blaney T, Craig RJ. Methadone maintenance. Does dose determine differences in outcome?. Journal of Substance Abuse Treatment. 1999;16:221–228
  3. Callon C, Wood E, Marsh D, Li K, Montaner J, Kerr T. Barriers and facilitators to methadone maintenance therapy use among illicit opiate injection drug users in Vancouver. Journal of Opioid Management. 2006;2:35–41
  4. China CDC, (2007). Personal communication.
  5. Chu TX, Levy JA. Injection drug use and HIV/AIDS transmission in China. Cell Research. 2005;15:865–869
  6. Chutuape MA, Silverman K, Stitzer ML. Use of methadone take-home contingencies with persistent opiate and cocaine abusers. Journal of Substance Abuse Treatment. 1999;16:23–30
  7. D'Aunno T, Pollack HA. Changes in methadone treatment practices: Results from a national panel study, l988–2000. JAMA. 2002;288:850–856
  8. Farré M, Mas A, Torrens M, Moreno V, Camí J. Retention rate and illicit opioid use during methadone maintenance interventions: A meta-analysis. Drug Alcohol Dependence. 2002;65:283–290
  9. Fiellin DA, O'Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Annals of Internal Medicine. 2002;137:688–692
  10. Flynn PM, Joe GW, Broome KW, Simpson DD, Brown BS. Looking back on cocaine dependence: Reasons for recovery. American Journal of Addiction. 2003;12:398–411
  11. Flynn PM, Porto JV, Rounds-Bryant JL, Kristiansen PL. Costs and benefits of methadone treatment in DATOS. Part 1: Discharged versus continuing clients. Journal of Maintenance of Addiction. 2003;2:129–149
  12. Gao SB. Experimental study on improving retention at second group of methadone maintenance treatment pilot clinics in Sichuan province. Beijing: Chinese Center for Disease Control and Prevention; 2006;
  13. Gill B, Okie S. China and HIV—A window of opportunity. The New England Journal of Medicine. 2007;356:1801–1805
  14. Gossp M, Trakada K, Steward D, et al. Reduction in criminal convictions after addiction treatment: 5-Year follow-up. Drug and Alcohol Dependence. 2005;79:295–302
  15. Hartel DM, Schoenbaum EE, Selwyn PA, Kline J, Davenny K, Klein RS, et al. Heroin use during methadone maintenance treatment: The importance of methadone dose and cocaine use. American Journal of Public Health. 1995;85:83–88
  16. Humeniuk R, Ali R. The first methadone clinic in Beijing. Drug and Alcohol Review. 2005;24:285–287
  17. Joe GW, Simpson DD, Broome KM. Effects of readiness for drug abuse treatment on client retention and assessment of process. Addiction. 1998;93:1177–1190
  18. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): A review of historical and clinical issues. Mount Sinai Journal of Medicine. 2000;67:347–364
  19. Kerr T, Marsh D, Li K. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Drug and Alcohol Dependence. 2005;80:329–335
  20. Kleber HD. Methadone maintenance 4 decades later: Thousands of lives saved but still controversial. JAMA. 2008;300:2303–2305
  21. Kulsudjarit K. Drug problem in Southeast and Southwest Asia. Annals of the New York Academy of Sciences. 2004;1025:446–457
  22. Li MQ, Lee SS, Gan ZG, Tan Yi, Meng JH, He ML. Achieving a high coverage—The challenge of controlling HIV spread in heroin users. Harm Reduction Journal. 2007;4:8
  23. Liu E, Liang T, Shen L, Zhong H, Wang B, Wu Z, et al. Correlates of methadone client retention: A prospective cohort study in Guizhou province, China. International Journal of Drug Policy. 2008;doi:10.1016/j.drugpo.2008.09.004
  24. Liu ZM, Lian Z, Zhou WH, Wang ZY. Knowledge and risk behaviours on HIV/AIDS among drug users in four areas in China. Chinese Journal on Drug Dependence. 2001;10:48–52
  25. Maddux JF, Prihoda TJ, Vogtsberger KN. The relationship of methadone dose and other variables to outcomes of methadone maintenance. The American Journal on Addictions. 1997;6:246–255
  26. Maxwell S, Shindemian MS. Optimizing long-term response to methadone maintenance treatment: A 152-week follow-up using higher-dose methadone. Journal of Addictive Diseases. 2002;21:1–12
  27. Merrill JO, Jackson TR, Schulman BA, Saxon AJ, Awan A, Kapitan S. Methadone medical maintenance in primary care. An implementation evaluation. Journal of General Internal Medicine. 2005;20:344–349
  28. Ministry of Health of China (MOH), Ministry of Public Security of China, and State Food and Drug Administration (SFDA) . Work plan of community maintenance treatment for opioid addicts. Retrieved January 31, 2009, from www.chinaaids.cn/worknet/download/2005/0308.doc2006;
  29. Pang L, Hao Y, Mi GD, Wang CH, Luo W, Rou KM, et al. Effectiveness of first eight methadone maintenance treatment clinics in China. AIDS. 2007;21:S103–S107
  30. Qian HZ, Schumacher JE, Chen HT, Ruan YH. Injection drug use and HIV/AIDS in China: Review of current situation, prevention and policy implications. Harm Reduction Journal. 2006;1:4
  31. Rhoades HM, Creson D, Elk R, et al. Retention, HIV risk, and illicit drug use during treatment: Methadone dose and visit frequency. American Journal of Public Health. 1998;88:34–39
  32. Sees KL, Delucchi KL, Masson C, Rosen A, et al. Methadone maintenance vs. 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial. JAMA. 2000;283:1303–1310
  33. Simpson DD, Joe GW, Brown BS. Treatment retention and follow-up outcomes in the Drug Abuse Treatment Outcomes Study (DATOS). Psychology of Addictive Behaviours. 1997;11:294–307
  34. Snijders TAB, Bosker RJ. Multilevel analysis: An introduction to basic and advanced multilevel modelling. Thousand Oaks, CA: Sage; 1999;
  35. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: A randomized trial. JAMA. 1999;281:1000–1005
  36. State Council Aids Working Committee Office, UN Theme Group on AIDS in China . A joint assessment of HIV/AIDS prevention, treatment and care in China. 2007;Beijing, China
  37. Stevens A, Radcliffe P, Sanders M, Hunt N. Early exit: Estimating and explaining early exit from drug treatment. Harm Reduction Journal. 2008;5:
  38. Sullivan GS, Wu Z. Rapid scale up of harm reduction in China. International Journal of Drug Policy. 2007;18:118–128
  39. Wang L. Comprehensively implement HIV/AIDS prevention and control regulation, promote community medicine maintenance treatment work. Retrieved Jan 24, 2009 from http://jmhe.jiangmen.gov.cn/ReadNews.asp?NewsID=18992006;
  40. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet. 1999;353:221–226
  41. White JM, Ryan CF, Ali RL. Improvements in retention rates and changes in client group with methadone maintenance streaming. Drug and Alcohol Review. 1996;15:83–88
  42. Wu Z. Landmark government methadone maintenance program in mainland China. In: 15th International AIDS Conference; Bangkok, Thailand; July 11–16. 2004;
  43. Wu Z. Methadone maintenance program in mainland China: From pilot to scale-up. In: International Conference on the Reduction of Drug Related Harm; Belfast, UK; March 20–24. 2005;
  44. Wu Z, Detels R, Zhang JP. Risk factors for intravenous drug use and sharing equipment among young male drug users in southwest China. AIDS. 1996;10:1017–1024
  45. Wu Z, Detels R, Zhang J, Li V, Li J. Community-based trial to prevent drug use among youths in Yunnan, China. American Journal of Public Health. 2002;92:1952–1957
  46. Wu Z, Sullivan S, Wang Y, Rotheram-Bonus MJ, Detels R. Evolution of China's response to HIV/AIDS. Lancet. 2007;369:679–690
  47. Zhang K, Ma S. Epidemiology of HIV in China: Intravenous drug users, sex workers, and large mobile populations are high risk groups. British Medical Journal. 2002;324:803–804

PII: S0740-5472(09)00148-2

doi: 10.1016/j.jsat.2009.09.002

Journal of Substance Abuse Treatment
Volume 38, Issue 2 , Pages 119-127 , March 2010

Article Tools